The United States insomnia pharmacological treatment market is projected to reach $4.24 billion by 2021 from $3.38 billion in 2016, growing at a CAGR [compound annual growth rate] of 4.6% from 2016 to 2021. This is according to Research and Markets’ report “U.S. Insomnia Market – Forecasts to 2021.”
In 2016, the prescription sleep aids segment is expected to account for the largest share of the United States insomnia pharmacological treatment market. The launch of Belsomra (Merck & Co Inc) in 2014 in the United States and the anticipated launch of E-2006 (Eisai Co Ltd) is expected to drive the growth of the market during the forecast years. However, due to the erosion in branded drugs sales and growing adoption of generics attributed to their low cost and equal efficacy as compared to branded products may hinder the growth of the market. In 2016, the zolpidem segment is expected to account for the largest share of the non-benzodaizepines prescription sleep aids market. However, higher adoption of generic products that are available are cheaper price is negatively affecting the growth of the market.
The over-the-counter (OTC) sleep aids segment of the United States insomnia pharmacological treatment market is expected to grow at the highest CAGR during the forecast period. Reasons attributing to the growth of this market include easier availability, low prices, and publicity regarding the side effects of the prescription sleep aids has also steered the patients towards OTC sleep aid.
This product is unbelievable and perfect for individuals who don’t want a sleeping pill but rather a fast dissolving sleep strips. A go to for psychiatrist and primary care physician getting away from the prescription drugs.